A new comprehensive report detailed the latest stats and trends in hypertension, coronary heart disease, stroke and many other areas of interest. “Progress in cardiovascular health depends on knowing where we stand,” the authors wrote. “To improve, we must measure—not occasionally, but consistently, transparently and with purpose.”

Based on feedback from the FDA, Aspire Biopharma plans on completing a multicenter clinical trial and then seeking regulatory approval for its new high-dose sublingual aspirin therapy. 

Early evidence suggests CBD could help clinicians treat pericarditis, myocarditis and other significant heart conditions. Additional research is still required, however, including many more clinical trials.

This news follows similar announcements from Humana, Cigna and UnitedHealthcare; a majority of insured Americans can now be treated with these technologies and have the procedure covered by their provider. 

The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

Researchers put an advanced AI model to the test, using it to evaluate the ECG results of more than 1,000 patients. It performed quite well. 

The new patch is implanted through a tiny incision and held in place with a biocompatible adhesive. It then helps the heart recover over time, replacing dead tissue that would typically never be able to regenerate.